Samavat Hamed, Newman April R, Wang Renwei, Yuan Jian-Min, Wu Anna H, Kurzer Mindy S
Department of Food Science and Nutrition, University of Minnesota, St. Paul, MN.
Division of Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute, Pittsburgh, PA.
Am J Clin Nutr. 2016 Dec;104(6):1671-1682. doi: 10.3945/ajcn.116.137075. Epub 2016 Nov 2.
Green tea has been suggested to improve cardiovascular disease risk factors, including circulating lipid variables. However, current evidence is predominantly based on small, short-term randomized controlled trials conducted in diverse populations.
The aim of this study was to examine the efficacy and impact of green tea extract (GTE) supplementation high in epigallocatechin gallate (EGCG) on blood lipids in healthy postmenopausal women.
This was an ancillary study of a double-blind, randomized, placebo-controlled, parallel-arm trial investigating the effects of a GTE supplement containing 1315 mg catechins (843 mg EGCG) on biomarkers of breast cancer risk. Participants were randomly assigned to receive GTE (n = 538) or placebo (n = 537) and were stratified by catechol-O-methyltransferase (COMT) genotype activity (high COMT compared with low or intermediate COMT genotype activity). They consumed either 4 GTE or identical placebo capsules daily for 12 mo. A total of 936 women completed this substudy. Circulating lipid panels including total cholesterol (TC), HDL cholesterol, and triglycerides were measured at baseline and at months 6 and 12.
Compared with placebo, 1-y supplementation with GTE capsules resulted in a significant reduction in circulating TC (-2.1% compared with 0.7%; P = 0.0004), LDL cholesterol (-4.1% compared with 0.9%; P < 0.0001) and non-HDL cholesterol (-3.1% compared with 0.4%; P = 0.0032). There was no change in HDL-cholesterol concentration, but triglyceride concentrations increased by 3.6% in the GTE group, whereas they decreased by 2.5% in the placebo group (P = 0.046). A significant reduction in TC was observed only among women with high (i.e., ≥200 mg/dL) baseline TC concentrations (P-interaction = 0.01) who consumed GTE capsules. The effect of GTE on the increase in triglycerides was mainly observed among obese women and statin users (P-interaction = 0.06).
Supplementation with GTE significantly reduced circulating TC and LDL-cholesterol concentrations, especially in those with elevated baseline TC concentrations. This trial was registered at clinicaltrials.gov as NCT00917735.
已有研究表明绿茶有助于改善心血管疾病风险因素,包括循环脂质变量。然而,目前的证据主要基于在不同人群中开展的小型短期随机对照试验。
本研究旨在探讨补充富含表没食子儿茶素没食子酸酯(EGCG)的绿茶提取物(GTE)对健康绝经后女性血脂的疗效和影响。
这是一项双盲、随机、安慰剂对照、平行组试验的辅助研究,该试验旨在研究一种含有1315 mg儿茶素(843 mg EGCG)的GTE补充剂对乳腺癌风险生物标志物的影响。参与者被随机分配接受GTE(n = 538)或安慰剂(n = 537),并根据儿茶酚-O-甲基转移酶(COMT)基因型活性进行分层(高COMT基因型活性与低或中等COMT基因型活性相比)。她们每天服用4粒GTE或相同的安慰剂胶囊,持续12个月。共有936名女性完成了这项子研究。在基线、第6个月和第12个月测量包括总胆固醇(TC)、高密度脂蛋白胆固醇和甘油三酯在内的循环脂质指标。
与安慰剂相比,补充GTE胶囊1年可显著降低循环TC(-2.1% 对比 0.7%;P = 0.0004)、低密度脂蛋白胆固醇(-4.1% 对比 0.9%;P < 0.0001)和非高密度脂蛋白胆固醇(-3.1% 对比 0.4%;P = 0.0032)。高密度脂蛋白胆固醇浓度没有变化,但GTE组甘油三酯浓度增加了3.6%,而安慰剂组降低了2.5%(P = 0.046)。仅在基线TC浓度高(即≥200 mg/dL)且服用GTE胶囊的女性中观察到TC显著降低(P交互作用 = 0.01)。GTE对甘油三酯升高的影响主要在肥胖女性和他汀类药物使用者中观察到(P交互作用 = 0.06)。
补充GTE可显著降低循环TC和低密度脂蛋白胆固醇浓度,尤其是基线TC浓度升高的人群。该试验已在clinicaltrials.gov上注册,注册号为NCT******。